Following FDA approval of its abbreviated new drug application, or ANDA, Dr. Reddy's Laboratories (NYSE:RDY) announced today that it launched its lamotrigine extended-release tablets, the generic version of GlaxoSmithKline's Lamictal. 

Lamotrigine is an anticonvulsant used to treat epilepsy and bipolar disorders. The generic-drug maker said it launched the drug on June 25 and the extended-release tablets are available in dosages of 25 mg, 50 mg, 100 mg, 200 mg, and 300 mg in 30-count bottles.

Dr. Reddy's Labs quotes IMS Health in noting the branded drug had domestic sales of approximately $300.5 million for the trailing 12-month period ending in April.